NexPoint - Investor Profile and Portfolio

Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.

Pioneering peptide therapeutics for traditionally undruggable cancer targets. This is a biopharmaceutical company focused on redefining druggability in oncology through innovative peptide therapeutics. They are developing SPEARs and SPARCs, acting inside and outside cancer cells, respectively. The company's pipeline includes first-in-class therapeutics targeting protein-protein interactions, with programs in Phase clinical trials. They are committed to delivering precision therapy and hope to patients and their families by targeting traditionally elusive oncogenic proteins. The company is involved in drug discovery, preclinical development, and clinical trials, aiming to create novel cancer treatments. They are leveraging peptide technology to develop targeted therapies for solid tumors and hematological diseases. The company is focused on research and development, clinical data presentation, and participation in healthcare conferences.

Manufacturer of compostable plant based resin and food service products. This business converts agricultural residues into bio-resin pellets for use in plastic manufacturing equipment. The resulting material serves as a substitute for petroleum-based plastics in the production of items such as cups, lids, cutlery, and straws. These products are designed to biodegrade in home composting environments. The process utilizes agricultural byproducts to create materials that function as drop-in replacements for conventional plastic manufacturing.